Skip to main content
IVVD logo

IVVD · Invivyd, Inc.

Track IVVD — free
$0.41 -0.03 (-7.45%) At close · Nov 20
Market Cap
$122.01M
Shares
295.63M
Volume · Nov 20 5.32M Avg daily vol (3M) 5.21M

Price & Indicators

 

Key stats

Close
$0.41
Fri 20 Nov
Open
$0.44
Fri 20 Nov
Average volume, 30 days
4.0M
shares a session
Short interest
36.2M
12.2% of shares · 9.7 days to cover
Day range
$0.41$0.47
Open $0.44 Close $0.41
52-week closing range
$0.41$2.88
Close $0.41 85.7% under the high
Short volume, last session
44%
Last earnings
Sep 29, 2026
Latest filing
10-Q · Nov 16
Price history
Aug 2021 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 16
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Substantial doubt about continuing as a going concern

Invivyd reported substantial doubt about continuing as a going concern after a $119.3 million net loss. PEMGARDA’s EUA is set to terminate on June 29, 2027; positive interim results could support a VYD2311 BLA submission.

Revenue $15.45M ▲ 17.7% Net loss $33.47M Diluted EPS -$0.10
Read from the MD&A section
4 source passages
Based on current operating plans and excluding future external financing, we will not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements beyond one year from the issuance date of the condensed consolidated financial statements in this Quarterly Report on Form 10-Q, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern. Since our inception, we have incurred significant losses, including a net loss of $119.3 million for the nine months ended September 30, 2026. Consequently, the EUA for PEMGARDA is set to terminate on June 29, 2027. In August 2025, we announced alignment with advice from the FDA on a compact and, therefore, rapid pathway to potential Biologics License Application (“BLA”) approval for VYD2311 for the prevention of COVID-19. Open the document at this passage
Nov 16
Current report 8-K
DECLARATION interim analysis data expected imminently

Invivyd said DECLARATION interim analysis data are expected imminently after discussions with the FDA. Q3 2026 PEMGARDA net product revenue rose 18% to $15.4 million, cash and cash equivalents were $126.4 million, and net loss was $33.5 million.

Financial results
4 source passages
Updated data timing driven by dialogue between Invivyd and the U.S. FDA 1) to refine details on the Accelerated Approval approach for VYD2311, and 2) to expand the accelerated regulatory approach and enable rapid development of future Invivyd monoclonal antibodies, including Invivyd’s measles antibody candidate; further update to be provided with DECLARATION interim analysis data Achieved Q3 2026 PEMGARDA® (pemivibart) net product revenue of $15.4 million, representing 18% growth versus Q3 2025 net product revenue of $13.1 million Q3 2026 ending cash and cash equivalents of $126.4 million Net loss was $33.5 million for the quarter ended September 30, 2026, compared to $10.5 million for the comparable period in 2025. Open the document at this passage
Sep 29
Current report 8-K
Other events

Invivyd said VYD2311 met all LIBERTY primary and secondary endpoints and showed superior safety and tolerability versus an mRNA COVID-19 vaccine; DECLARATION safety and immunogenicity data are expected in October 2026 to support a planned FDA BLA via Accelerated Approval.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$60.69M
Trailing 12 months
Net income (TTM)
−$130.33M
Trailing 12 months
Revenue growth YoY
+17.7%
Year over year
Operating margin
-224.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-109.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$126.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+89.5%
Year over year · more shares
Price change (1Y)
-82.8%
Trailing year
Short interest
12.2%
Latest settlement · 9.7 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −61%
below
Price vs 50-day avg −40%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −33%
trailing
6-month return −64%
trailing
YTD return −83%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.25% of shares out · ▼ -2.3% MoM · 9.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
136 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Strong
Revenue growth +110%
Y/Y
EPS growth +79%
Y/Y
Free cash flow $-58.3M
Quant / Vol
risk profile
Very High
Volatility 102%
annualized · 1-yr
Max drawdown −86%
past year
ATR 14.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−61% Bearish
Price vs 50-day avg
−40% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+7% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
12.25% of shares out · ▼ -2.3% MoM · 9.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
136 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $3
vs 200-day avg -61% vs 50-day avg -40%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
VBY329 $8K three months ended September 30, 2026 filing —
VMS063 $1.05M three months ended September 30, 2026 filing —
VYD2311 $8.35M three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IVVD
Invivyd, Inc.
this stock
$122.01M -83.3% +110.5% — 12.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
136
% held
73.9%
Net QoQ
-13.9M sh
Top holder
JANUS HENDERSON GROUP PLC
Held Float
View
Held by Funds
Fund positions
85
View
Short & Settlement
Short Interest Falling
Shares short
36.2M
Days to cover
9.7d
Change
-842.1K sh
View
Short Volume
Short vol %
44%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
48.2K
Value
$28.9K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
65.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$53.4M
Net income (FY)
$-52.5M
EPS diluted
$-0.30
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
21

Invivyd said DECLARATION interim analysis data are expected imminently after discussions with the FDA. Q3 2026 PEMGARDA net product revenue rose 18% to $15.4 million, cash and cash equivalents were $126.4 million, and net loss was $33.5 million.

View
Proposed Sales
Value
$27.2K
Shares
37.7K
Filed
Aug 17, 2026
View
Exempt Offerings
Offering
$23.7M
Filed
Nov 29, 2022
View
Earnings & Events
Webcasts
Last webcast
Sep 29, 2026
View
Investor Relations
Latest news
Invivyd Reports Inducement Grants…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
IVVD -29.1% -32.7% -63.8% -29.1% -83.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -20.5% -23.5% -54.6% -20.3% -84.5%
Key facts CIK 1832038 CUSIP 00534A102 13F (30d) 144 filings 126 filers Visit website Investor relations